Literature DB >> 15818752

c-src activating mutation analysis in Chinese patients with colorectal cancer.

Ye-Xiong Tan1, Han-Tao Wang, Peng Zhang, Zhong-Hua Yan, Guan-Long Dai, Meng-Chao Wu, Hong-Yang Wang.   

Abstract

AIM: To investigate the occurrence of cellular src (c-src) activating mutation at codon 531 in colorectal cancer patients from Chinese mainland.
METHODS: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay followed by sequencing and single-strand conformation polymor-phism analysis were carried out to screen 110 samples of primary colorectal cancer and 20 colorectal liver metastases.
RESULTS: Only one sample showed PCR-RFLP-positive results and carried somatic codon 531 mutations. No additional mutation of c-src exon 12 was found.
CONCLUSION: c-src codon 531 mutation in colorectal cancer is not the cause of c-src activation.

Entities:  

Mesh:

Year:  2005        PMID: 15818752      PMCID: PMC4305825          DOI: 10.3748/wjg.v11.i15.2351

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis.

Authors:  William Rengifo-Cam; Akio Konishi; Naoki Morishita; Hidetada Matsuoka; Takao Yamori; Shigeyuki Nada; Masato Okada
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

Review 2.  A renaissance for SRC.

Authors:  Timothy J Yeatman
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.

Authors:  W R Cam; T Masaki; Y Shiratori; N Kato; T Ikenoue; M Okamoto; K Igarashi; T Sano; M Omata
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

4.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

5.  Overexpression of the csk gene suppresses tumor metastasis in vivo.

Authors:  T Nakagawa; S Tanaka; H Suzuki; H Takayanagi; T Miyazaki; K Nakamura; T Tsuruo
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

6.  Elevated c-Src protein expression is an early event in colonic neoplasia.

Authors:  S Iravani; W Mao; L Fu; R Karl; T Yeatman; R Jove; D Coppola
Journal:  Lab Invest       Date:  1998-03       Impact factor: 5.662

7.  Activating SRC mutation in a subset of advanced human colon cancers.

Authors:  R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

8.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Authors:  M S Talamonti; M S Roh; S A Curley; G E Gallick
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 9.  SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Authors:  Markus Warmuth; Robert Damoiseaux; Yi Liu; Doriano Fabbro; Nathanael Gray
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

10.  Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients.

Authors:  L Laghi; P Bianchi; O Orbetegli; L Gennari; M Roncalli; A Malesci
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  2 in total

1.  Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers.

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Kelli Monteiro da Costa; Jhenifer Santos Dos Reis; José Osvaldo Previato; Lucia Mendonça Previato; Leonardo Freire-de-Lima
Journal:  Glycoconj J       Date:  2022-02-14       Impact factor: 2.916

2.  Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

Authors:  H Wang; B Liu; A Q O Al-Aidaroos; H Shi; L Li; K Guo; J Li; B C P Tan; J M Loo; J P Tang; M Thura; Q Zeng
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.